Pharmaceutical companies are exploiting populations year-after-year, fine tuning the name of illnesses annually and marketing new cures that only make people sicker. Beginning this fall, Japan will introduce a self-amplifying mRNA COVID-19 vaccine as part of its vaccination program for the 2024-2025 fall and winter seasons. The vaccine, Kostaive (ARCT-154), will be available for 7,000 yen ($47) to individuals aged 65 and older, as well as those aged 60 to 64 with severe underlying health conditions. It is part of a two-dose series.

In clinical trials, a near 90 percent adverse event rate was recorded after the first dose. These adverse events were disregarded, however, as Japan approved the jab. The United States is also looking to approve these jabs in the coming years.

World’s first self-amplifying mRNA vaccine will be released in Japan

ARCT-154 became the world’s first self-amplifying mRNA COVID-19 vaccine after receiving approval from Japan’s Ministry of Health, Labour, and Welfare in November 2023. It was developed by biotechnology firm CSL in collaboration with Arcturus Therapeutics.

Unlike mRNA vaccines — which only produce the spike protein necessary for immune response as long as the mRNA persists — saRNA vaccines are engineered to create copies of themselves and the proteins they encode. This "biological printing press" could theoretically amplify the vaccine’s presence and multiply its effects within the body indefinitely.

According to CSL, the vaccine demonstrated higher immunogenicity and a favorable safety profile compared to original mRNA vaccines during clinical trials. However, independent vaccine researchers are voicing serious concerns regarding the safety and efficacy of this untested technology.

Dr. Nicolas Hulscher stated, “These products are completely new. There is absolutely no long-term safety data on them.” In trials for ARCT-154, he noted a near 90 percent adverse event rate after the first dose, with clinicians observing significant systemic reactions in participants. Serious and medically-attended adverse events were only recorded from Day 1 to Day 92.

Karina Acevedo Whitehouse, a microbiology professor, emphasized the lack of comprehensive studies on the long-term effects of self-amplifying mRNA technology. She pointed out that there are no assessments of potential cellular transformations, including the risks of cancerous mutations or inflammatory responses. “We simply do not know what the consequences could be,” she warned.

“There have also been no studies conducted on trans-generational effects — for instance, teratogenicity [birth defects] — of self-amplifying mRNA injections,” she said. “We simply do not know what the consequences could be.”

Further raising concerns, a Cambridge University study revealed that original mRNA vaccines could trigger unintended immune responses in a third of recipients, leading to possible autoimmune reactions. Whitehouse linked the increase in certain cancers observed since 2021 to the effects of mRNA technology on cellular pathways.

Self-amplifying mRNA vaccines, which include an enzyme that allows for the replication of the injected mRNA, may pose even greater risks than the original mRNA vaccines. Experts suggest that the sustained antigen production could lead to heightened risks, making these new vaccines akin to “conventional mRNA injections on steroids,” as Hulscher described.

U.S. considers using self-amplifying mRNA vaccines, which are really runaway bioweapons

The United States is planning to use these new vaccines. The Biden regime has already partnered with several companies to develop self-amplifying mRNA vaccines for future plandemics. In other words, companies are conspiring to create a line of self-amplifying vaccines so they can profit from future virus constructs and subsequent pandemic messaging and vaccine marketing campaigns. CastleVax, Codagenix and Gritstone Bio have already received contracts from the Department of Health and Human Services under the federal government’s Project NextGen.

Project NextGen claims to accelerate and streamline the rapid development of the next generation of vaccines and treatments by spearheading public-private collaborations. In September of 2023, Gritstone Bio locked in a $433 million contract to simply “conduct a mid-stage study of its self -amplifying mRNA COVID-19 vaccine candidate,” so there have been products in development for some time. Gritstone Bio has previously received funding from the Bill and Melinda Gates Foundation, which seeks to capitalize on their vaccine investments. Gritstone Bio’s partners also include BlackRock and State Street, official partners of the World Economic Forum. These bioweapon investments are too-big-to-fail, and the courts are not holding vaccine manufacturers accountable for harming millions, so it's likely that saRNA vaccines will be coming to the U.S. soon.

Sources include:

ChildrensHealthDefense.org

WhiteHouse.gov

Nature.com

Link

Another successful Theta Hackathon has been completed, with a brilliant group of winning projects in the AI, video, and gaming sectors! We thank all the awesome developers and teams that submitted projects to this edition of Theta Hackathon, helping to build the decentralized future of AI in media and entertainment. In the coming weeks, we’ll be highlighting all the top projects.

Next up is the Video / Rendering track winner, TPLAY.

TPLAY is a social network for sharing videos, built on Theta Network. It lets users upload or create AI-generated videos, participate in contests, and win exciting prizes. This innovative platform transforms the way users create, share, and interact with video content, offering a unique blend of technology and creativity. Join in this new era of decentralized video sharing and discover the endless possibilities with TPLAY. It’s as simple as its tagline: Share. Compete. Win.

https://vimeo.com/987662545

Platform Description

TPLAY is not just another video-sharing platform; it is a dynamic ecosystem that empowers users to take full control of their content and its potential. With TPLAY, you can:

Share Your Videos:

• Upload and share your video content securely and efficiently.
• Leverage decentralized storage solutions to ensure your content is always accessible and tamper-proof.

Generate Videos with AI:

• Utilize advanced AI tools to create captivating video content effortlessly.
• Enhance your videos with AI-generated effects, edits, and enhancements, making your content stand out in the crowd.

Win Prizes Based on User Engagement:

• Participate in weekly contests where your video content competes for audience engagement.
• Earn rewards from a base prize pool funded by TPLAY, plus additional user subscription fees for contest entry.
• Engage your audience and climb the leaderboard to win exciting prizes and gain recognition.

Use Interactive and Engaging Features:

• Like, comment, and share videos within the community to drive engagement and support your favorite creators.
• Receive real-time updates and notifications about contest standings, video processing, and more.
• Store video cover images securely with Theta Edge Store, making your content easily retrievable and visually appealing.

Technical Overview

The application architecture leverages modern web technologies and integrates with the Theta Network blockchain for various functionalities.

User Interaction:

• Users access the TPLAY web application through a browser.
• Users connect their decentralized wallet (e.g., MetaMask) to authenticate and interact with the platform.

Video Upload and Processing:

• Users upload videos through the web application.
• The web application sends the video data to the backend, which queues the video for processing.
• Video Services handle the processing and storage of video content on the Theta Edge Network.

Blockchain Interactions:

• The web application interacts with deployed smart contracts on the Theta Network for handling tokens and contests.
• TNT TPlay Token transactions are facilitated for ecosystem interactions.
• Contest smart contracts manage contest entries, prize pools, and reward distribution.

Data Storage:

• User and video metadata are stored in a PostgreSQL database.
• Video cover images are stored in the Theta Edge Store for decentralized access and retrieval.

AI and Webhook Services:

• AI services generate video content as needed.
• Webhook services handle real-time updates and notifications related to video processing and contests.

Future planned improvements to TPLAY include introducing more sophisticated AI tools for video creation and enhancement, establishing a DAO where users can propose new features and vote on platform changes, a Video Studio Creator which will be a powerful tool that allows users to edit, enhance, and generate videos with ease, and transitioning to a fully decentralized storage solution, ensuring complete security, transparency, and user control over data.

Congratulations Matteo, Dario, Francesco C., and Francesco M., and thank you for your contributions to the Theta Ecosystem!

Link

Japanese startup Gu Group said it signed a memorandum of understanding with Aozora Bank to ‘consider’ issuing stablecoins. Japan has three different types of stablecoins, with banks capable of issuing two of them – either deposit tokens or trust-based stablecoins where the assets are ring-fenced and held on behalf of the issuer. This agreement is for trust-based stablecoins. Additionally, Aozora also invested Yen 150 million ($1 million), bringing the total Gu Group backing to Yen 1 billion ($6.7 million).

Gu Group is the founder of Japan Open Chain, an Ethereum compatible public blockchain where the nodes are operated by enterprises. The validators include Sony subsidiary Corgear, NTT Docomo, Dentsu and Fukuoka Financial’s digital bank, Minna no Ginko.

One of Gu’s subsidiaries has developed the Gu Coin Studio for the issuance and distributions of stablecoins and is designed to link to existing accounting systems.

Gu previously ran a stablecoin trial with three smaller banks, Minna no Bank, which is now a blockchain validator, Tokyo Kiraboshi Financial Group and Shikoku Bank.

Aozora Bank has other indirect digital currency interests. GMO Aozora Net Bank is the first bank participant in the DCJPY initiative, the Japanese tokenized deposit platform, which was launched in late August. Aozora owns half of GMO Aozora Net Bank, but its partner GMO is an investor in DCJPY’s creator, DeCurret.

Meanwhile, one of the most interesting stablecoin initiatives out of Japan, was the recent announcement by Progmat Coin that Japan’s big three banks will use stablecoins for cross border payments. Rather than getting clients to use wallets, they will initiate payments in the conventional way, and the banks will use the stablecoins behind the scenes.

Link